Ultragenyx Pharmaceutical (RARE) Return on Invested Capital (2018 - 2025)
Ultragenyx Pharmaceutical (RARE) has disclosed Return on Invested Capital for 8 consecutive years, with 15.21% as the latest value for Q4 2025.
- On a quarterly basis, Return on Invested Capital rose 1700.0% to 15.21% in Q4 2025 year-over-year; TTM through Dec 2025 was 15.21%, a 1700.0% increase, with the full-year FY2025 number at 6.16%, down 412.0% from a year prior.
- Return on Invested Capital was 15.21% for Q4 2025 at Ultragenyx Pharmaceutical, up from 6.83% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 15.21% in Q4 2025 to a low of 7.38% in Q3 2023.
- A 5-year average of 1.4% and a median of 1.69% in 2024 define the central range for Return on Invested Capital.
- Peak YoY movement for Return on Invested Capital: tumbled -631bps in 2023, then surged 1700bps in 2025.
- Ultragenyx Pharmaceutical's Return on Invested Capital stood at 0.41% in 2021, then tumbled by -287bps to 1.59% in 2022, then tumbled by -132bps to 3.7% in 2023, then skyrocketed by 52bps to 1.79% in 2024, then soared by 949bps to 15.21% in 2025.
- Per Business Quant, the three most recent readings for RARE's Return on Invested Capital are 15.21% (Q4 2025), 6.83% (Q3 2025), and 3.44% (Q2 2025).